J&J CEO Won't Take Stand In Risperdal Breast-Growth Trial

Law360, Philadelphia (September 20, 2012, 7:32 PM EDT) -- Johnson & Johnson CEO Alex Gorsky will not be forced to take the stand in a trial set to begin Monday alleging a boy developed breasts after being treated with the antipsychotic drug Risperdal, a Pennsylvania state judge ruled Thursday.

Judge Arnold New of the Philadelphia Court of Common Pleas granted a motion from J&J division Janssen Pharmaceuticals Inc., agreeing to quash a subpoena directed at Gorsky by attorneys for the teenage plaintiff.

The teenager’s case, one of more than 80 pending in the court, accuses...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.